Abstract
A study was conducted to evaluate the role of exhaled carbon monoxide (CO) levels in the management of patients with mild and moderate persistent bronchial asthma. Spirometry, exhaled CO measurements and symptom scoring was done before and after four weeks of treatment with inhaled corticosteroids. Exhaled CO levels were significantly elevated in patients of mild as well as moderate persistent asthma as compared to controls but the levels did not correlate with the disease severity. After four weeks of treatment, there was a decrease in exhaled CO levels in both the groups but the decrease was not found to be statistically significant. Therefore, clinically exhaled CO level is not a useful marker in bronchial asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
